

FINANCE *for* GROWTH

AN IN-DEPTH, FAST-PACED COURSE IN FINANCE & VALUATION IN LIFE SCIENCES & HEALTH

7 Intensive Modules Over 7 Weeks from
October 31st to December 12th 2025

EXPAND YOUR KNOWLEDGE ON FINANCE & VALUATION IN LIFE SCIENCES & HEALTH

Understanding financial concepts and business valuation is critically important in Life Sciences & Health industry. Whether you are an entrepreneur seeking funding for your start-ups, a tech transfer officer, a business analyst, a consultant, policy advisor evaluating business proposals and business cases, or PhD or Post Docs looking to kick-start a career in finance, this in-depth crash course will increase your understanding and expand your knowledge on valuating companies in Life Sciences & Health sector. This course is organized by Vrije Universiteit Amsterdam.

Dive into real-world case studies from the Life Sciences & Health sector and master the essentials of strategic financing, valuation, and the incorporation.



AN INITIATIVE OF

PROMOTION PARTNER

ECTS CREDITED

The course has a study load of 6 ECTS (168 hours).


PARTICIPANT PROFILE

- Biotech & Medtech Founders
- Tech Transfer Officers
- Investment Analysts
- Policy makers
- Consultants
- Business Analysts
- PhD Students & Post Docs
- Alliance Managers

PROGRAMME COVERING:

- Financial statement analysis
- Making a convincing business case
- Financial feasibility: calculations & valuation
- Negotiating & VC deal terms
- The time value of money and capital budgeting
- Scaling up: financial requirements and best practice
- Securing an exit: the role of investment bankers

READY TO BOOST YOUR FINANCIAL SKILLS?



Register now -
spots are limited!

For more information and registration:

www.hyphenprojects.nl/f4g

EXPAND YOUR KNOWLEDGE ON FINANCE & VALUATION IN LIFE SCIENCES & HEALTH

Below is the preliminary program for the course.
Keep up to date, subscribe to our newsletter! >>>>>



MODULE	TOPICS	TEACHERS	CONTENT
Module 1. 31 October 2025 The basics of strategic funding: market trends and financial statement analysis	Course introduction and setting the scene: biopharma market trends, drivers & opportunities	Linda van de Burgwal / Kenneth Fernald	Introduction to the Finance for Growth course and why the biopharma market differs from traditional markets in terms of financing
	Financial statement analysis	Marc Schauten / Arjen Siegmann	What to learn from financial statements? The basics of reading and interpreting balance sheets, profit and loss statements and cash flow statements
Module 2. 7 November 2025 Negotiating a deal: smart calculations, the time value of money, and deal terms	Discounted cash flow analysis	Marc Schauten / Arjen Siegmann	Conducting smart calculations with a common spreadsheet tool: advanced use of Excel functions
	Venture capital deal terms	Harm de Vries / Fien Hogewoning / Rogier Ketelaars	What to look for when negotiating with venture capital? The most often used venture capital deal terms and the most overlooked clauses
Module 3. 14 November 2025 Financial feasibility: capital budgeting, financing of early stage ventures and getting new products reimbursed	Investment risk and the cost of capital	Marc Schauten / Arjen Siegmann	Why the profits in pharma need to be high: the time value of money and capital budgeting
	Non-dilutive funding	Judith Smit / Isabella Zampeta	How do I finance a business? Applying the dilutive and non-dilutive funding mix to finance life sciences ventures
Module 4. 21 November 2025 The impact of risk and return: cost of capital and valuation by VCs	Introduction to options	Marc Schauten / Arjen Siegmann	To understand optionality this lecture introduces financial options. They provide the intuition and the machinery to deal with real options (week 6).
	Valuation by VCs	Bart Bergstein	How do venture capitalists value companies before they invest? Experiences from a seasoned investor.
Module 5. 28 November 2025 Valuating your company: valuation approach and industry specific margins	Valuation techniques for the firm	Marc Schauten / Arjen Siegmann	How to determine the value of a company
	Valuations for life sciences and industry specific methods	Kenneth Fernald	Valuation approaches for life sciences ventures - DCF and rNPV method; industry specific calculations and risk profiling
Module 6. 5 December 2025 Securing an exit: perspectives of investment bankers and valuation of M&A deals	Real options	Marc Schauten / Arjen Siegmann	When it might be better to wait. Using real options in the biopharma sector
	Valuation by investment bankers	Van Lanschot-Kempen	How do investment bankers value companies in order to get to an exit? A real-life example.
	Q&A	Linda van de Burgwal / Kenneth Fernald	Opportunity to ask questions
Module 7. 12 December 2025 Get active: understanding and applying 24 financing modalities while optimizing your company's position	Financing modalities for the firm	Linda van de Burgwal	Understanding and applying over 24 financing modalities for your firm (emphasis on non-dilutive instruments)
	How to scale up sensibly	Pieter Wijffels	How to balance R&D with sales & marketing in the life science industry
	Q&A	Linda van de Burgwal / Kenneth Fernald	Opportunity to ask questions